Calico

Executive Summary

Calico is a biotechnology company established in 2013 with a mission to understand the biology of aging and develop interventions for age-related diseases. Backed by Alphabet Inc., the company operates from South San Francisco and employs a unique long-term research model that integrates deep basic science with translational drug discovery. Calico is currently in Phase 1 clinical development, focusing on small molecule therapies targeting fundamental aging pathways. The company’s approach combines extensive genomic and proteomic analysis with advanced drug discovery platforms to identify and validate novel targets. By addressing the underlying mechanisms of aging, Calico aims to develop treatments that can delay or prevent multiple age-associated conditions, including neurodegenerative diseases, cancer, and metabolic disorders. The company’s strong financial backing from Alphabet provides it with the resources to pursue ambitious, long-term research programs that are often beyond the scope of traditional biotech firms. As Calico advances its pipeline, it has the potential to revolutionize the treatment of age-related diseases by targeting their root causes rather than just symptoms, positioning itself as a leader in the emerging field of geroscience.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 clinical data readout for lead small molecule program targeting aging biology40% success
• Q4 2026New partnership or collaboration with a major pharmaceutical company to advance aging biomarkers60% success
• Q3 2026Publication of key preclinical results demonstrating efficacy in age-related disease models70% success